Reply: Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control. Issue 3 (10th March 2022)

• Record Type: Journal Article
• Authors: Porter, Joanna C.; Win, Thida; Erlandsson, Kjell; Thielemans, Kris; Groves, Ashley M.
• Is Part Of: European respiratory journal. Volume 59:Issue 3(2022)
• Publication Date: 2022-03-10
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.03124-2021
• Languages: English
• ISSNs: 0903-1936

Abstract

We thank P-S. Bellaye and co-workers for their considered and insightful response. Given their finding of [ 18 F]fluoromisonidazole ([ 18 F]F-MISO) uptake in the bleomycin mouse model of fibrosis [1], we too were surprised not to demonstrate a similar signal in patients with idiopathic pulmonary fibrosis (IPF). However, as acknowledged, there are other examples of positron emission tomography (PET) tracers, such as cis-4-[ 18 F]-fluoro-l -proline, yielding PET signals in animal lung fibrosis models that have not been replicated in humans with fibrotic lung disease [2, 3]. In vivo PET imaging in IPF patients shows no significant evidence of lung tissue hypoxia https://bit.ly/3fywY7K